Sugi Predict

Sugi Predict / Compounds / SCHEMBL3110686

SCHEMBL3110686

SCHEMBL3110686

O=c1ccc(-c2cccc([N+](=O)[O-])c2)n[nH]1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.60
▸ IDO1 P14902 1/20 0.58
▸ MAPT P10636 5/20 0.56
▸ LMNA P02545 3/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CASP6 P55212 1/20 0.53
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ PGR P06401 2/20 0.50
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ TSHR P16473 1/20 0.47
▸ KEAP1 Q14145 1/20 0.47
▸ NFE2L2 Q16236 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30047706 1.00 SMN1; SMN2 (0.60) SMN1; SMN2IDO1MAPTLMNACYP1A2
SCHEMBL10353459 0.82 CYP1A2 (0.74) SMN1; SMN2MAPTLMNACYP1A2MEN1
SCHEMBL3103600 0.81 LMNA (0.59) MAPTLMNACYP1A2CASP6MEN1
SCHEMBL1830545 0.79 SMN1; SMN2 (0.64) SMN1; SMN2IDO1MAPTLMNAMEN1
SCHEMBL1852084 0.78 IDO1 (0.61) SMN1; SMN2IDO1MAPTLMNAMEN1
SCHEMBL7298232 0.76 CYP1A2 (0.65) SMN1; SMN2MAPTLMNACYP1A2MEN1
SCHEMBL11629881 0.75 MAPT (0.52) SMN1; SMN2IDO1MAPTLMNAMEN1
SCHEMBL30048131 0.75 SMN1; SMN2 (0.70) SMN1; SMN2IDO1MAPTLMNAMEN1
SCHEMBL11153190 0.75 MAPT (0.56) SMN1; SMN2IDO1MAPTLMNAMEN1
SCHEMBL9976036 0.75 LMNA (0.68) SMN1; SMN2IDO1MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346604-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS REVERE PHARMACEUTICALS 2025-11-13 — — US disclosed
US-20250235453-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS REVERE PHARMACEUTICALS 2025-07-24 — — US disclosed
WO-2024091473-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS REVERE PHARMACEUTICALS (US) 2024-05-02 — — WO disclosed
WO-2024091473-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS REVERE PHARMACEUTICALS (US) 2024-05-02 — — WO disclosed
WO-2023076259-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS REVERE PHARMACEUTICALS (US) 2023-05-04 — — WO disclosed
WO-2023076259-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS REVERE PHARMACEUTICALS (US) 2023-05-04 — — WO disclosed
US-8367668-B2 Pyridazinone derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-02-05 — — US disclosed
US-8367668-B2 Pyridazinone derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-02-05 — — US disclosed
US-8367668-B2 Pyridazinone derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-02-05 — — US disclosed
US-20100179148-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-07-15 — — US disclosed
EP-2150539-A1 PYRIDAZINONE DERIVATIVES Merck Patent GmbH (DE) 2010-02-10 — — EP disclosed
WO-2008145243-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2008-12-04 — — WO disclosed
WO-2008145243-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2008-12-04 — — WO disclosed
WO-2008030744-A2 INHIBITORS OF C-MET AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-03-13 — — WO disclosed
US-4892873-A MUSCLE RELAXANTS, ANTIEPILEPTIC, AN XIOLYTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1990-01-09 — — US disclosed
US-4767765-A ANXIOLYTIC OR ANTIEPILEPTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1988-08-30 — — US disclosed
EP-0223974-A1 N-Substituted-N-[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-phenyl]alkanamides, carbamates and ureas AMERICAN CYANAMID COMPANY (US) 1987-06-03 — — EP disclosed
US-4654343-A USEFUL AS ANXIOLYTIC OR ANTIEPILEPTIC AGENTS AS WELL AS SEDATIVE-HYPNOTIC AND SKELETAL MUSCLE RELAXANT AGENTS AMERICAN CYANAMID COMPANY (US) 1987-03-31 — — US disclosed
US-4117130-A 6-PHENYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES AMERICAN CYANAMID COMPANY (US) 1978-09-26 — — US disclosed
US-4112095-A 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents AMERICAN CYANAMID COMPANY (US) 1978-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179148-A1 PYRIDAZINONE DERIVATIVES MET, ERBB2, RET SMN1; SMN2 3373/4885IDO1 1092/4885MAPT 4114/4885
US-20250346604-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS RAC1, TNK2, GDI2 SMN1; SMN2 2356/4885IDO1 4418/4885MAPT 1537/4885
US-20250235453-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS RAC1, TNK2, GDI2 SMN1; SMN2 2356/4885IDO1 4418/4885MAPT 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.